Imipenem resistance of Pseudomonas in pneumonia: A systematic literature review

44Citations
Citations of this article
99Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Pneumonia, and particularly nosocomial (NP) and ventilator-associated pneumonias (VAP), results in high morbidity and costs. NPs in particular are likely to be caused by Pseudomonas aeruginosa (PA), ~20% of which in observational studies are resistant to imipenem. We sought to identify the burden of PA imipenem resistance in pneumonia.Methods: We conducted a systematic literature review of randomized controlled trials (RCT) of imipenem treatment for pneumonia published in English between 1993 and 2008. We extracted study, population and treatment characteristics, and proportions caused by PA. Endpoints of interest were: PA resistance to initial antimicrobial treatment, clinical success, microbiologic eradication and on-treatment emergence of resistance of PA.Results: Of the 46 studies identified, 20 (N = 4,310) included patients with pneumonia (imipenem 1,667, PA 251; comparator 1,661, PA 270). Seven were double blind, and 7 included US data. Comparator arms included a β-lactam (17, [penicillin 6, carbapenem 4, cephalosporin 7, monobactam 1]), aminoglycoside 2, vancomycin 1, and a fluoroquinolone 5; 5 employed double coverage. Thirteen focused exclusively on pneumonia and 7 included pneumonia and other diagnoses. Initial resistance was present in 14.6% (range 4.2-24.0%) of PA isolates in imipenem and 2.5% (range 0.0-7.4%) in comparator groups. Pooled clinical success rates for PA were 45.2% (range 0.0-72.0%) for imipenem and 74.9% (range 0.0-100.0%) for comparator regimens. Microbiologic eradication was achieved in 47.6% (range 0.0%-100.0%) of isolates in the imipenem and 52.8% (range 0.0%-100.0%) in the comparator groups. Resistance emerged in 38.7% (range 5.6-77.8%) PA isolates in imipenem and 21.9% (range 4.8-56.5%) in comparator groups.Conclusions: In the 15 years of RCTs of imipenem for pneumonia, PA imipenem resistance rates are high, and PA clinical success and microbiologic eradication rates are directionally lower for imipenem than for comparators. Conversely, initial and treatment-emergent resistance is more likely with the imipenem than the comparator regimens. © 2010 Zilberberg et al; licensee BioMed Central Ltd.

References Powered by Scopus

Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia

0
5565Citations
N/AReaders
Get full text

Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia

860Citations
N/AReaders
Get full text

Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005

755Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

2468Citations
N/AReaders
Get full text

Pseudomonas aeruginosa: Resistance to the max

636Citations
N/AReaders
Get full text

Mechanisms of antimicrobial resistance in Gram-negative bacilli

332Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zilberberg, M. D., Chen, J., Mody, S. H., Ramsey, A. M., & Shorr, A. F. (2010). Imipenem resistance of Pseudomonas in pneumonia: A systematic literature review. BMC Pulmonary Medicine, 10. https://doi.org/10.1186/1471-2466-10-45

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 33

60%

Researcher 11

20%

Professor / Associate Prof. 9

16%

Lecturer / Post doc 2

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 31

62%

Agricultural and Biological Sciences 7

14%

Immunology and Microbiology 7

14%

Biochemistry, Genetics and Molecular Bi... 5

10%

Save time finding and organizing research with Mendeley

Sign up for free